Establishment Labs’ (ESTA) “Overweight” Rating Reiterated at Stephens

Establishment Labs (NASDAQ:ESTA)‘s stock had its “overweight” rating restated by Stephens in a research report issued on Thursday,Benzinga reports. They currently have a $52.00 price target on the stock. Stephens’ price objective suggests a potential upside of 23.96% from the stock’s previous close.

Establishment Labs Stock Down 9.2 %

ESTA stock opened at $41.95 on Thursday. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The stock has a market cap of $1.21 billion, a P/E ratio of -16.26 and a beta of 0.95. The business’s 50-day moving average price is $37.53 and its 200-day moving average price is $41.38. Establishment Labs has a twelve month low of $28.16 and a twelve month high of $60.12.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. On average, equities research analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $27,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Establishment Labs by 1.8% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 35,236 shares of the company’s stock valued at $1,525,000 after buying an additional 632 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $36,000. Federated Hermes Inc. increased its position in shares of Establishment Labs by 3.0% in the fourth quarter. Federated Hermes Inc. now owns 32,720 shares of the company’s stock valued at $1,507,000 after buying an additional 953 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Establishment Labs by 2.7% in the fourth quarter. Swiss National Bank now owns 38,500 shares of the company’s stock valued at $1,774,000 after buying an additional 1,000 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.